Dermata in Development with DMT210 and DMT220 for Rosacea

[Guide]

Dermata has announced the following treatments in development for rosacea: 

"DMT210 is our topical gel formulation of DMT200. Due to the wide distribution of GPCRs in the skin we plan to develop DMT210 for the treatment of rosacea, atopic dermatitis and acne vulgaris.

Rosacea: DMT210 has demonstrated downregulation of toll-like receptor 2 (TLR2), lowering IL-8 production, which ultimately would reduce erythema associated with rosacea.  Moreover, DMT210 also exhibits a reduction in IL-6, which is a powerful inflammatory mediator.  Thus, DMT210 has the potential to be the first topical treatment to reduce both the erythema and the inflammation (papules and pustules) of rosacea.

DMT220, which is currently being formulated, will be our novel ophthalmic formulation.  We plan to develop DMT220 for the treatment of ocular rosacea, because it can be treated by dermatologists.

Ocular Rosacea: The ocular surface is also populated with GPCRs, suggesting that a topical ophthalmic formulation using DMT200 could be effective at targeting similar pathways as in the skin.  Therefore, since the same inflammatory processes that occur in dermal rosacea are also expressed in ocular rosacea, there is good scientific rationale to develop DMT220 for ocular rosacea."

For more info